JO
FOMX

John Overdeck’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

John Overdeck’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-91,656
Closed -$344K – 3843
2019
Q1 		$344K Buy
+91,656
New +$343K ﹤0.01% 2515

Other funds holding FOMX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

John Overdeck's FOMX Position: Q2 2019 in Review

John Overdeck sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q2 2019, closing a stake of 91,656 shares — an estimated $344K sold.

John Overdeck first reported a position in FOMX in Q1 2019 and held it in 1 quarter. The position peaked at $344K in Q1 2019. 58 funds tracked by Wall St. Rank hold FOMX as of Q2 2019.

  • John Overdeck reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q2 2019 after selling out during the quarter.
  • John Overdeck sold 91,656 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q2 2019, an estimated $344K.
  • John Overdeck first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2019 and held it in 1 quarter.
  • John Overdeck's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $344K in Q1 2019.
  • 58 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q2 2019.

Based on Two Sigma Investments's 13F filing for Q2 2019, filed 14 Aug 2019.